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Tuberculosis is a very serious respiratory infectious disease, 
caused by the bacillus Mycobacterium tuberculosis, which gener-
ates a relevant societal and clinical burden. It has always repre-
sented a permanent concern and a public health challenge over 
the course of human history, because of its severe epidemiological, 
and economic-financial implications. The present review aims at 
over-viewing the impact of tuberculosis on the Israeli healthcare 
system, its temporal trend and evolution, stratified according to 
ethnicities and minorities, the need of establishing new facilities 
and implementing screening techniques, public health strategies 
and diagnostic tests, following massive immigration waves from 
countries characterized by a high incidence rate of tuberculo-
sis during the fifties-sixties until the nineties, and the policies 
implemented by the Israeli government in the control, manage-
ment and treatment of tuberculosis, as well as the role played by 
Israeli prominent scientists in discovering new druggable targets 
and finding bioactive compounds and bio-molecules in the fight 
against tuberculosis. Israel represents a unique, living labora-
tory in which features of developed and developing countries mix 
together. This country as a case-study of immigrant, pluralistic 
society underlines the importance of adopting a culturally-sensi-
tive community intervention approach. The understanding of the 
subtle interplay between race/ethnic host and pathogen factors, 
including the role of gene variations and polymorphisms can pave 
the way for a personalized treatment and management of tuber-
culosis patients, contributing to the development of new tools for 
targeted tuberculosis therapeutics, immunodiagnostics and vac-
cination products.
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Introduction
Tuberculosis (TB) is a very serious respiratory infec-
tious disease, caused by the bacillus Mycobacterium tu-
berculosis (M. tuberculosis), which generates a relevant 
societal and clinical burden. It has always represented a 
permanent concern and a public health challenge over 
the course of human history, because of its severe epi-
demiological, and economic-financial implications [1]. 
More in detail, according to the latest available “Global 
Tuberculosis Report” published in 2019 by the World 
Health Organization (WHO) [2], TB is one of the top 
ten causes of death worldwide and the leading cause 
of mortality across all infections, followed by the hu-
man immunodeficiency virus (HIV)/acquired immuno-
deficiency syndrome (AIDS). Specifically, in 2018, 10 
million people have become ill, 484,000 have developed 
multidrug resistant TB and 1 million and half have died. 
The present review aims at over-viewing the impact of 
TB on the Israeli healthcare system, its temporal trend 
and evolution, stratified according to ethnicities and 
minorities, the need of establishing new facilities and 
implementing screening techniques, public health strate-
gies and diagnostic tests [3-5], following massive im-
migration waves from countries characterized by a high 
incidence rate of TB during the fifties-sixties [6, 7] un-
til the nineties [8-10], and the policies implemented by 
the Israeli government in the control, management and 
treatment of TB [8], as well as the role played by Is-
raeli prominent scientists in discovering new druggable 
targets and finding bioactive compounds and bio-mole-
cules in the fight against TB [11]. 
Israel as pluralistic society
Globalization has profound, complex effects on human 
health [12]. Living “in an ever more connected global 
village linked through international travel, politics, eco-
nomics, culture and human-human and human-animal 
interactions” [13] may result in a widespread diffusion 
of communicable disorders, including monkey pox, “se-
vere acute respiratory syndrome” (SARS), avian influ-
enza and TB outbreaks. 
Israel represents a complex, multicultural and pluralistic 
society characterized by the co-existence of sometimes 
clashing and opposite tendencies, lifestyles and habits. 
More in detail, Israel comprises two major ethno-na-
tional groups, Israeli Jews and Israeli Arabs, with about 
79% and 21 of the population being Jewish and Arabs, 
respectively. 
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The two groups profoundly differ in terms of religious, 
social and cultural values as well as ideologies and con-
structs: for example, whereas Israeli Arabs hold highly 
traditional collectivist values and a cohesive culture, 
Western codes and values profoundly influence Israeli 
Jews. Furthermore, the two groups reside in two geo-
graphically different areas and settings, using separate 
social and cultural networks, like schools, educational 
organizations and religious institutions, as well as mass 
media, social networks and other channels [14]. 
Additionally, these differences and discrepancies be-
tween the two groups reflect in various levels of health 
literacy and in the usage of healthcare services and pro-
visions: Israeli Arabs tend to underutilize healthcare fa-
cilities and medical support when compared with Israeli 
Jews. Different factors may explain this, including the 
lack of proper information and knowledge concerning 
the delivery of healthcare services and provisions, per-
ceived barriers, like language and stigma, as well as a 
preference for alternative, non-conventional treatments 
(including religious/traditional management of the dis-
ease) and informal social support. For instance, Arab-
Israeli patients tend to seek medical advice and consult 
physicians with a two-fold delay with respect to Jews, 
due to lower educational level and distrust in the Western 
remedies and treatments.
Health literacy can be, as such, considered as a proxy of 
use of healthcare provisions and empirical studies have 
shown how low literacy, especially among vulnerable 
segments of the population and minorities, translates in-
to underutilized preventive services, low immunization 
practice and vaccination coverage [15, 16].
These differences reflect also, as we will see in the next 
paragraphs, in different incidence/prevalence rates of 
TB.
Tuberculosis and ethnicity
Both host and pathogen factors play a key role in de-
termining innate immune responses to M. tuberculosis, 
even though their roles are yet to be fully established 
from a cellular and molecular standpoints. Furthermore, 
there is a dearth of data concerning the interplay of eth-
nicity, pathogen strain and immune response. 
Nahid and colleagues [17] have assessed host mac-
rophage immune responses of 3 different ethnicities 
(namely, Filipino, Chinese and non-Hispanic White 
subjects) to 3 genetically and geographically diverse M. 
tuberculosis lineages. Authors found that Filipino mac-
rophages released less amounts of interleukin type 1 (IL-
1), IL-6, and higher concentrations of IL-8, when com-
pared to macrophages from the other two ethnicities, 
whereas the levels of IL-10, IL-12p70, tumor necrosis 
factor alpha (TNF-_) and granulocyte-macrophage col-
ony-stimulating factor (GM-CSF) did not significantly 
vary according to race/ethnic factors. Ethnicity affected 
the response to the Toll-like receptor 2 agonist lipotei-
choic acid (TLR2/LTA) and TLR4 agonist lipopolysac-
charide (TLR4/LPS). 
This research, together with a consistent body of stud-
ies, has led Aravindan [18] to formulate the hypothesis 
that TB represents a “genetically primed and determined 
infectious disease”, with polymorphisms of a number of 
genes – including the natural resistance-associated mac-
rophage protein type 1 (NRAMP-1/SLC11A1), the vita-
min D receptor (VDR), the low molecular weight poly-
peptide/transporter with antigen processing, the chemo-
kine monocyte chemoattractant protein type 1 (CCL-2/
MCP-1), the immunity-related GTPase family M protein 
type 1 (IRGM-1), IL-1, several interleukins, such as IL-
8, IL-10, IL-12, TLR, nucleotide-binding oligomeriza-
tion domain-containing protein type 2 (NOD-2), hu-
man leukocyte antigen (HLA), mannose-binding lectin 
(MBL), major histocompatibility complex (MHC), TNF, 
the purinoceptor P2X7, epiregulin, the SP110 nuclear 
antigen, and interferon gamma (IFN-a) – finely tune and 
modulate immune response and progression from infec-
tion to disease.
Tuberculosis in Israel
Specifically concerning Israel, according to the 2019 
“Global Tuberculosis Report”, the incidence rates of TB 
and multidrug resistant TB are 4.0 [95%CI 3.4-4.6] and 
0.36 [95%CI 0.20-0.58] cases per 100,000 people, re-
spectively [2]. 
However, in the fifties-sixties the incidence rate was 
much higher, reaching 200 cases per 100,000 popula-
tion, due to a massive arrival of refugees from a post-war 
Europe and North-African countries [8].
Regarding the seventies-eighties, Dolberg and coau-
thors [19] and Greene and coworkers [20] performed 
a 10-year survey at the Soroka Medical Center (Be’er 
Sheva, Negev), from 1978 to 1987, identifying 279 
TB cases (67% pulmonary and 33% extra-pulmonary; 
48% affecting Ethiopian Jews, 28% and 24% involv-
ing Bedouin Arabs and Jews of other origins, respec-
tively). In terms of socio-demographic characteristics, 
the Bedouin and Ethiopian patients were younger, 
had fewer co-morbidities, with mainly pulmonary 
TB, but were less adherent to pharmacological treat-
ment. Furthermore, the Ethiopian patients have been 
hospitalized longer than other ethnic groups. Authors 
concluded that clinical presentations of TB could vary 
according to ethnicity, reflecting the diversity of the 
population, combining characteristics of both a devel-
oping and a developed country.
Concerning the nineties, according to the epidemio-
logical observational, retrospective study performed be-
tween 1999 and 2011 by Bishara and colleagues [21], 
the incidence of TB in native ethnic minorities could 
remain high also in developed, high-income countries. 
More in detail, authors found 831 cases of TB among 
Israeli-born individuals: 530 (64%) and 301 cases (36%) 
affecting Israeli Jews and Israeli Arabs, respectively, 
with an average annual TB rate of 1.1 and 1.6 cases per 
100,000 population, respectively, which was lower than 
the national average (7.0 cases per 100,000 population). 
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Thanks to the adoption of effective public health policies 
and strategies, TB rates began to decline both in Israel 
Arabs and Israel Jews, until they converged to 1 case per 
100,000 people, even though ethnicity reflected in subtle 
differences in terms of clinical presentation and symp-
toms. For instance, Israel Arabs tended to be older, were 
more likely to have pulmonary TB and to report a lower 
treatment success rate when compared to Israel Jews. 
However, increasing older age and HIV co-infection 
status were independent predictors of treatment success 
rate, differently from ethnicity. 
Summarizing, differences related to race/ethnic factors, 
initially particularly striking among some minorities, 
have begun to decrease over the time until convergence. 
For instance, treatment success rate has become rather 
high and satisfactory in various ethnic groups, and has 
not been associated with race/ethnic factors.
This has been possible thanks to profound changes 
in TB-related policies. In the nineties, Daniel Weiler-
Ravell, expert in pulmonary and internal medicine, 
and Daniel Chemtob, a clinical epidemiologist, have 
obtained the chairs of the “National Advisory Com-
mittee on Tuberculosis” within the Israeli Ministry of 
Health (MOH) [4,8]. To cope with an increasing TB 
incidence rate, due to massive immigration from coun-
tries such as Ethiopia and geographic regions of the 
former Soviet Union, Israeli government has decided 
to centralize TB centers offering ad hoc services for 
immigrants, and to adopt the “Directly Observed Ther-
apy, Short course” (DOTS) approach recommended 
by the WHO. In 1993, the “Advisory Committee on 
Tuberculosis” was settled, in 1994 a National Coor-
dinator was designated, followed by cost-driven, pop-
ulation-based strategies for improving management 
and plans to increase adherence to treatment in 1995. 
Always in 1995, major epidemiological studies have 
documented the reality, providing the stakeholders, 
policy- and decision-makers with numbers to substan-
tiate their decisions. In 1996 the scandal of the “Blood 
Affair”, in which Ethiopians’ donated blood had been 
secretly discarded for more than a decade since 1984, 
resulted in the establishment of a National “Tubercu-
losis and AIDS unit” and in new laws and regulations 
being enforced. Together with juridical provisions, 
in 1997 economic-financial and budgetary plans en-
abled the creation of new infrastructures and facilities 
specifically devoted to the fight against TB. This was 
followed by the release of national clinical and orga-
nizational guidelines, informing, in an evidence-based 
fashion, healthcare workers of the most effective and 
appropriate management options for TB patients.
Interestingly, these efforts have paralleled the issue 
of the “National Health Insurance Law”, which has 
dramatically transformed the country and led to the 
establishment of four healthcare maintenance orga-
nizations (HMOs) or health providers, making insur-
ance universal and not anymore on voluntarily ba-
sis [4, 8]. 
Future challenges
Israeli scientists have pioneered discoveries that could 
profoundly impact on the management and treatment of 
TB patients. A group of researchers at the Weizmann In-
stitute of Science and Technology, including Shelly Hen-
Avivi, Roi Avraham and Noa Bossel Ben Moshe  [22], 
have made efforts to dissect the complex interactions 
between different host immune cell types underlying the 
outcome of the immune response to M tuberculosis in-
fection, exploiting the latest advancements in the field 
of single cell RNA-sequencing (scRNA-seq). Authors 
have developed and implemented dynamic deconvolu-
tion algorithms using bulk scRNA-seq measurements of 
infected human peripheral blood cells. 
The use of artificial intelligence and new machine learn-
ing-based techniques appears promising in advancing 
the treatment of TB and predicting its insurgence and 
progression by means of predictive biomarkers [23]. 
Other major challenges that need to be addressed are:
a) the need of new facilities and tools to implement and 
expand the access of Arabic population and other mi-
norities to TB centers; 
b) the emergence of drug/multidrug-resistant TB strains 
related to migration and/or climate change [24].
Conclusion
Israel represents a unique, living laboratory in which 
features of developed and developing countries mix 
together. This country as a case-study of immigrant, 
pluralistic society underlines the importance of adopt-
ing a culturally-sensitive community intervention ap-
proach [25, 26].
The understanding of the subtle interplay between race/
ethnic host and pathogen factors, including the role of 
gene variations and polymorphisms can pave the way 
for a personalized treatment and management of TB pa-
tients, contributing to the development of new tools for 
targeted TB therapeutics, immunodiagnostics and vac-
cination products [27].
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